(redirected from Antibody therapeutics)
Also found in: Dictionary, Medical, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Words related to antibody

References in periodicals archive ?
Among the therapeutic areas, the oncology segment led the global next-generation antibody therapeutics market in 2014, with the largest market size, but the autoimmune/inflammatory is expected to see the fastest growth of 46.
CytomX Therapeutics is a biotechnology company focused on revolutionizing the monoclonal antibody field by creating a new generation of highly targeted antibody therapeutics.
com/research/wwvgs8/advances_in) has announced the addition of the "Advances in monoclonal antibody therapeutics " report to their offering.
ALD403 is Alder's calcitonin gene-related peptide (CGRP) inhibiting antibody therapeutic for treatment of migraine.
a privately held biotherapeutics company focused on the development of best-in-class bi-specific antibody therapeutics and multi-valent protein therapeutics, today announced the completion of a common share offering totaling $11.
New analysis from Frost & Sullivan, Advances in Monoclonal Antibody Therapeutics (http://bit.
Currently there is a significant research effort to develop monoclonal antibody therapeutics to treat a range of diseases including cancer, inflammatory and autoimmune disorders," continued Dr.
RuiYi is focused on the discovery and development of novel antibody therapeutics with upsized potential that represent (1) first in class antibody therapeutics to GPCR targets validated with small molecules yet never successfully drugged and (2) best in class antibody therapeutics to validated targets for unique markets with significant medical need.
Vancouver, Canada, a privately-held biomedical company, have announced a collaboration through which the two companies expect to utilize Medarex's HuMAb-Mouse technology to develop fully human antibody therapeutics for central nervous system disorders.
com) announces updates to their Antibody Therapeutics database.
com/research/9n5sj5/bispecific) has announced the addition of the "Bispecific Antibody Therapeutics Market (2nd Edition), 2014 - 2024" report to their offering.
have formed an alliance to develop fully human antibody therapeutics.
Our platform provides key competitive advantages in antibody optimization and discovery, enabling us to build a pipeline of antibody therapeutics with best-in-class potential.
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, achieved the first research milestone in its antibody therapeutics alliance with MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX), announced in February 2013.
The novel discovery format is analogous to a combinatorial chemistry library and enables direct cell based screening, opening novel targets to antibody therapeutics like G-protein coupled receptors or ion channels.
Full browser ?